First results of molecular imaging (FDG and FES) in prospective study for selecting second line hormonotherapy in estrogen receptors positive metastatic breast cancer patients - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue European Journal of Nuclear Medicine and Molecular Imaging Année : 2019

First results of molecular imaging (FDG and FES) in prospective study for selecting second line hormonotherapy in estrogen receptors positive metastatic breast cancer patients

Résumé

Aim/Introduction: About 70% of primitive breast cancers had positive estrogen receptors (ER) and may benefit from hormonotherapy. However, ER expression in breast cancer metastases is heterogeneous and about 15% of metastases lost this expression over time. Biopsies were not possible systematically. 16α-18Fluoro-17β-Oestradiol (18FES) is a radiopharmaceutical which predict the response to the first line hormonotherapy. The aim of this prospective study (NCT03442504) was to determine the predictive value of PET at the patient level, before a second line hormonotherapy (2nd- HT) on the FDG response obtained at 6 weeks of treatment. Materials and Methods: We prospectively included 12 ER+ metastatic breast cancer patients, HER2 negative, in progression despite first line hormonotherapy. For the complete study, 60 patients will be included. Due to 2nd-HT proposed by oncologist, we performed 18FES PET-CT (18FES-BL) and 18FDG PET-CT (18FDG-BL) at baseline in the month before the new treatment introduction. Follow-up with 18FDG PET-CT and CT

Domaines

Cancer
Fichier principal
Vignette du fichier
OP-284 EANM2019.pdf (252.62 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

inserm-02337440 , version 1 (29-10-2019)

Identifiants

  • HAL Id : inserm-02337440 , version 1

Citer

B. Maucherat, A. Leduc-Pennec, N. Fleury, Ludovic Ferrer, E. Bourbouloux, et al.. First results of molecular imaging (FDG and FES) in prospective study for selecting second line hormonotherapy in estrogen receptors positive metastatic breast cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 (1), pp.S117. ⟨inserm-02337440⟩
64 Consultations
21 Téléchargements

Partager

Gmail Facebook X LinkedIn More